Compare 3M Company (MMM) vs BIO-TECHNE Corp (TECH) Price & Performance

3M CompanyTrade

BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

3M Company vs BIO-TECHNE Corp — how do they compare? 3M Company trades at $170.75 (market cap $82.99B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: 3M Company is far larger — about 7.4× BIO-TECHNE Corp's market cap, and 3M Company pays the higher dividend (1.96%). Which is the better fit depends on your goals.

	MMM	TECH
Market Cap	$82.99B	$11.16B
Sector	Industrials	Health
52-Week High	$174.61	$72.12
52-Week Low	$141.10	$43.31
Enterprise Value	$91.39B	$11.24B
Dividend Yield	1.96%	0.45%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MMM

3M beats Q2 earnings and raises outlook, driven by growth in optics and industrial segments.Seeking Alpha · 5 hours agoBullish 3M shares jump 10% after beating Q2 earnings and raising full-year EPS forecastGordon Thompson · 6 hours agoBullish 3M shares jump 9% after Q2 earnings beat and raised 2026 guidanceProactive Investors · 11 hours agoBullish View details →

TECH

View details →

About 3M Company

3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.